Critical Phenomena at the Antiferromagnetic Phase Transition of Azurite

We report on high-resolution acoustic, specific-heat and thermal expansion measurements in the vicinity of the antiferromagnetic phase transition at T_N = 1.88 K on a high-quality single crystal of the natural mineral azurite. A detailed investigation of the critical contribution to the various quantities at T_N is presented. The set of critical exponents and amplitude ratios of the singular contributions above and below the transition indicate that the system can be reasonably well described by a three-dimensional Heisenberg antiferromagnet.Comment: 9 pages, 3 figures, proceedings of ICM 2012, JKP

Evidence of exactness of the mean field theory in the nonextensive regime of long-range spin models

The q-state Potts model with long-range interactions that decay as 1/r^alpha subjected to an uniform magnetic field on d-dimensional lattices is analized for different values of q in the nonextensive regime (alpha between 0 and d). We also consider the two dimensional antiferromagnetic Ising model with the same type of interactions. The mean field solution and Monte Carlo calculations for the equations of state for these models are compared. We show that, using a derived scaling which properly describes the nonextensive thermodynamic behaviour, both types of calculations show an excellent agreement in all the cases here considered, except for alpha=d. These results allow us to extend to nonextensive magnetic models a previous conjecture which states that the mean field theory is exact for the Ising one.Comment: 10 pages, 4 figure

Five-loop additive renormalization in the phi^4 theory and amplitude functions of the minimally renormalized specific heat in three dimensions

We present an analytic five-loop calculation for the additive renormalization constant A(u,epsilon) and the associated renormalization-group function B(u) of the specific heat of the O(n) symmetric phi^4 theory within the minimal subtraction scheme. We show that this calculation does not require new five-loop integrations but can be performed on the basis of the previous five-loop calculation of the four-point vertex function combined with an appropriate identification of symmetry factors of vacuum diagrams. We also determine the amplitude functions of the specific heat in three dimensions for n=1,2,3 above T_c and for n=1 below T_c up to five-loop order. Accurate results are obtained from Borel resummations of B(u) for n=1,2,3 and of the amplitude functions for n=1. Previous conjectures regarding the smallness of the resummed higher-order contributions are confirmed. Borel resummed universal amplitude ratios A^+/A^- and a_c^+/a_c^- are calculated for n=1.Comment: 30 pages REVTeX, 3 PostScript figures, submitted to Phys. Rev.

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

The study is a randomized phase II trial investigating graft-versus-host disease prophylaxis after non-myeloablative (90 mg/m(2) fludarabine and 2 Gy total body irradiation) human leukocyte antigen matched unrelated donor transplantation. Patients were randomized as follows: arm 1 – tacrolimus 180 days and mycophenolate mofetil 95 days (n=69); arm 2 – tacrolimus 150 days and mycophenolate mofetil 180 days (n=71); arm 3 – tacrolimus 150 days, mycophenolate mofetil 180 days and sirolimus 80 days (n=68). All patients had sustained engraftment. Grade II-IV acute graft-versus-host disease rates in the 3 arms were 64%, 48% and 47% at Day 150, respectively (arm 3 vs. arm 1 (hazard ratio 0.62; P=0.04). Owing to the decreased incidence of acute graft-versus-host disease, systemic steroid use was lower at Day 150 in arm 3 (32% vs. 55% in arm 1 and 49% in arm 2; overall P=0.009 by hazard ratio analysis). The Day 150 incidence of cytomegalovirus reactivation was lower in arm 3 (arm 1, 54%; arm 2, 47%; arm 3, 22%; overall P=0.002 by hazard ratio analysis). Non-relapse mortality was comparable in the three arms at two years (arm 1, 26%; arm 2, 23%; arm 3, 18%). Toxicity rates and other outcome measures were similar between the three arms. The addition of sirolimus to tacrolimus and mycophenolate mofetil is safe and associated with lower incidence of acute graft-versus-host disease and cytomegalovirus reactivation. (clinicaltrials.gov identifier: 00105001)

Use of light scattering in characterizing reactively ion etched profiles

Currently, profile control in plasma etching of submicron structures requires inspection of cleaved samples by scanning electron microscopy. This is time consuming, destructive, and limited to a small subset of processed wafers. We show that light scattering can be used to rapidly characterize submicron differences in reactively ion etched, periodic Si structures. A similar approach has been used previously to monitor etching rates and undercutting using specular and first order diffraction peaks. Here, we measure all orders scattered over 180° as a function of incident angle and polarization and focus on the use of this technique coupled with statistical methodology to distinguish subtle changes in line profile. Although scatter from grating test patterns is examined here, this method should also be applicable to complex, submicron device structures

Tricritical Point and the Doping Dependence of the Order of the Ferromagnetic Phase Transition of La1-xCaxMnO3

We report the doping dependence of the order of the ferromagnetic metal to paramagnetic insulator phase transition in La1-xCaxMnO3. At x = 0.33, magnetization and specific heat data show a first order transition, with an entropy change (2.3 J/molK) accounted for by both volume expansion and the discontinuity of M ~ 1.7 Bohr magnetons via the Clausius-Clapeyron equation. At x = 0.4, the data show a continuous transition with tricritical point exponents alpha = 0.48+/- 0.06, beta = 0.25+/- 0.03, gamma = 1.03+/- 0.05, and delta = 5.0 +/- 0.8. This tricritical point separates first order (x<0.4) from second order (x>0.4) transitions.Comment: 14 pages, including 4 figures: i.e. 10 pages of text and 4 pages of figures. to appear in Physical Review Letters (accepted

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

BACKGROUND: Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD. METHODS: We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56. RESULTS: A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P<0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]). CONCLUSIONS: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy